Navigation Links
AHRQ Director Carolyn Clancy and Dr. Mark McClellan to Address Device Executives 2009 MDMA Annual Meeting
Date:4/14/2009

WASHINGTON, April 14 /PRNewswire-USNewswire/ -- Medical device industry leaders, lawmakers, and government officials will gather for the 2009 Annual Meeting of the Medical Device Manufacturers Association (MDMA) June 1st - 3rd at the Park Hyatt in Washington, D.C.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO)

The MDMA Annual Meeting will bring together executives from innovative entrepreneurial medical technology companies and healthcare's most influential and respected decision makers. Understanding the impact of industry and government trends has never been more important, and we encourage all industry executives to attend. Participants will learn how to respond to current industry challenges and seize available opportunities. The meeting will focus on stimulating new ideas, promoting innovation, and offering solutions in the changing spectrum of medical technology.

Dr. Mark McClellan, with the Brookings Institute and former CMS Administrator, will address healthcare reform at the opening reception; while Carolyn Clancy, the Agency for Healthcare Research and Quality's Director; David Cassak, Windhover Information's Managing Partner; and Andrew Hirshfeld, Acting Deputy Commissioner for Patent Examination Policy at the U.S. Patent and Trademark Office will speak during MDMA's general sessions. Meeting attendees will also hear from panels comprised of seasoned experts from Capitol Hill, the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and industry.

In addition to healthcare reform, FDA issues and comparative effectiveness research, this meeting will feature sessions on improving the US patent system, developing a comprehensive compliance program, international opportunities and challenges, and many more issues affecting smaller medical technology companies.

"I encourage all industry executives to attend this premier industry event and join MDMA and its member companies in our Nation's Capital" said Joe Kiani, Chairman and CEO of Masimo Corporation. "The meeting and congressional fly-in provide a unique opportunity for entrepreneurs to directly engage policymakers on Capitol Hill."

More information on the agenda, venue, accommodations and registration can be found online at www.medicaldevices.org, or by calling MDMA at (202) 354-7172. Members may attend for $795 and non members for $995. Medical Device Companies with sales under $500,000 can join MDMA by registering for the Annual Meeting at the non member rate. Register and start receiving member benefits today.

The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, D.C. representing innovators and entrepreneurs in the medical device industry. MDMA seeks to improve the quality of patient care by encouraging the development of new medical technology and fostering the availability of innovative products in the marketplace.


'/>"/>
SOURCE Medical Device Manufacturers Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
2. HealthInsuranceFinders.com Launches Video Contest for Young Directors
3. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
4. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
5. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
6. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
7. Nick Childs Joins Grey New York as Director of Content Development
8. New Director of Nursing Practice Named for Nurses Association
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. William Moore Appointed to IRIDEX Board of Directors
11. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: